SeraNovo is a drug formulation company specializing in oral drug delivery and bioavailability enhancement for BCS Class II/IV and bRo5 compounds. Our NanoGlass™ technology solves oral bioavailability challenges for small molecules, PROTACs and molecular glues. Through our ExpoSure™ program, we generate in vivo-ready formulations within 2 weeks using minimal API and have demonstrated up to 5x higher bioavailability versus traditional amorphous solid dispersions. SeraNovo has supported programs for AstraZeneca, Johnson & Johnson, Boehringer Ingelheim, Arvinas, and C4 Therapeutics.